$27.52
+2.11 (+8.30%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XNCR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
30 interventional · 4 with posted results
Held by 12 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, Hudson Bay Capital Management LP, +7 more) · FINRA short interest 8.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid TumorsNCT07593092Incidence of Adverse EventsOpen-label · Treatment | Phase 1 | Recruiting | Biological: XmAb541, XmAb808 | Ovarian Cancer | 90 | Dec 2028 | ≤ 864 d | 2026-08-13 |
| A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesNCT07284797Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Open-label · Treatment | Phase 1 | Recruiting | Biological: XmAb657 | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | Oct 2028 | ≤ 803 d | 2026-08-03 |
| A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisNCT07230353PrimaryOpen-label · Treatment | Phase 1 | Recruiting | Biological: Plamotamab | Rheumatoid Arthritis | 68 | Jun 2028 | ≤ 680 d | 2026-08-03 |
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisNCT06619990Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb942 in healthy volunteers (Part A)Randomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Biological: XmAb942 · Drug: Placebo | Ulcerative Colitis (UC) | 270 | Apr 2028 | ≤ 619 d | 2026-07-24 |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsNCT06276491Incidence of adverse eventsOpen-label · Treatment | Phase 1 | Recruiting | Biological: XmAb541 | Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor | 282 | Dec 2027 | ≤ 498 d | 2026-06-11 |
| Study of XmAb412 in Healthy ParticipantsNCT07713485Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb412 in healthy adult participants (Part A and Part B)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: XmAb412 Monoclonal Bispecific Antibody, Placebo | Not Applicable - Healthy Adult Participants | 128 | May 2027 | ≤ 284 d | 2026-08-03 |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaNCT05433142Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)Open-label · Treatment | Phase 1 | Recruiting | Biological: XmAb819 | Clear Cell Renal Cell Carcinoma | 307 | Feb 2027 | ≤ 192 d | 2026-08-03 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesNCT05032040PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohortsOpen-label · Treatment | Phase 2 | Active, not recruiting | Biological: vudalimab | Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 170 | 2025-10-15 | — | 2025-02-07 |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCNCT06173505Part 1: Recommended Phase 2 dose of vudalimab in combination with chemotherapyRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Business Decision | Combination product: Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed | Nonsquamous Non-small Cell Lung Cancer | 28 | 2025-12-24actual | — | 2026-03-13 |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Combination product: vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel · Biological: vudalimab monotherapy | Metastatic Castration-Resistant Prostate Cancer | 72 | 2025-06-10actual | — | 2026-05-05 |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Completed | Biological: XmAb®808, Keytruda® (pembrolizumab) | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer | 60 | 2025-05-20actual | — | 2025-08-07 |
| A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid TumorsNCT05996445Incidence of dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The Sponsor made a business decision to end the study. | Biological: XmAb662, Keytruda® (pembrolizumab) | Solid Tumors | 7 | 2024-05-21actual | — | 2024-08-23 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesNCT02924402Safety and tolerability as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: XmAb13676 | B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | 154 | Apr 2024actual | — | 2024-11-13 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic DermatitisNCT06005792To evaluate the safety and tolerability of multiple ascending dose subcutaneous (SC ) administration of XmAb27564Randomized · Double-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business Decision | Biological: XmAb27564, Placebo | Psoriasis, Atopic Dermatitis | 23 | 2024-03-22actual | — | 2025-12-02 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03Randomized · Open-label · Treatment | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2024-02-15actual | — | 2024-07-05 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)NCT05328102results2024-04-30Part 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study has been terminated early by the sponsor due to business decision. | Biological: Plamotamab, Tafasitamab · Drug: Lenalidomide | Diffuse Large-cell B-cell Lymphoma | 3 | 2023-02-21actual | — | 2024-04-30 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2023-02-16actual | — | 2023-03-30 |
| Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy VolunteersNCT04857866Incidence of treatment-emergent adverse events, graded by CTCAE Version 5.0Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: XmAb27564, Placebo | Safety in Healthy Volunteers | 48 | 2022-11-10actual | — | 2023-03-01 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717Open-label · Treatment | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2022-06-01actual | — | 2022-12-01 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerNCT04590781results2023-04-20Number of Participants With Treatment-emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The study has been terminated early by the sponsor due to business decision. | Biological: XmAb18087 · Drug: XmAb18087 ± Pembrolizumab | Merkel Cell Carcinoma, Small Cell Lung Cancer | 4 | 2022-03-24actual | — | 2023-04-20 |
| A Study of XmAb®18087 in Subjects With NET and GISTNCT03411915Determine the safety and tolerability profile of XmAb18087Open-label · Treatment | Phase 1 | Completed | Biological: XmAb18087 | Neuroendocrine Tumor, Gastrointestinal Neoplasm | 62 | 2021-10-26actual | — | 2022-05-10 |
| PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesNCT02730312Safety as determined by the number of participants with treatment-related adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: XmAb14045 | Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis | 120 | Sep 2021actual | — | 2022-03-08 |
| Study Evaluating AMG 424 in Subjects With Multiple MyelomaNCT03445663Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Previous sponsor business decision not to proceed with the AMG 424 asset. | Drug: AMG 424 | Relapsed/ Refractory Multiple Myeloma | 27 | 2020-06-19actual | — | 2023-03-07 |
| A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus ErythematosusNCT02725515results2019-08-09Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: XmAb5871, Placebo to match XmAb5871 | Systemic Lupus Erythematosus | 105 | 2018-07-17actual | — | 2019-08-20 |
| Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)NCT02725476results2018-12-07Proportion of Patients With an Improvement in IgG4-RD ActivityOpen-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Completed | Biological: XmAb5871 | IgG4-RD | 20 | Dec 2017actual | — | 2018-12-07 |
| Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195NCT02881853Bioavailability of SC XmAb7195 after 4 once-weekly doses as measured by the ratio of dose-normalized SC XmAb7195 area under the concentration-time curve (AUC) to dose-normalized IV XmAb7195 AUC.Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: XmAb7195, Placebo | Healthy Volunteers, Atopic Disease | 57 | 2017-02-24actual | — | 2017-07-11 |
| XmAb5871 Bioavailability StudyNCT02867098Cmax, Maximum observed serum concentrationNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: XmAb5871 | Healthy Volunteers | 50 | 2016-10-21actual | — | 2017-12-08 |
| Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic DermatitisNCT02148744Number of adverse events including type and severityRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: XmAb7195, Placebo | Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis | 72 | 2015-09-21actual | — | 2017-01-24 |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic LeukemiaNCT01161511To determine the dose limiting toxicitiesOpen-label · Treatment | Phase 1 | Completed | Biological: XmAb5574 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 27 | Jan 2013actual | — | 2014-04-21 |
| Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell LymphomaNCT00606645Identification of the maximum tolerated dose and identification of the recommended dose of XmAb®2513 for evaluation in future studies.Open-label · Treatment | Phase 1 | Completed | Biological: XmAb2513 | Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | 23 | Apr 2010actual | — | 2014-04-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19